effect of biochemical markers of bone turnover for treating and predicting fracture risk risk of metabolic bone disease

effect of biochemical markers of bone turnover for treating and predicting fracture risk risk of metabolic bone disease - effect of biochemical markers of bone turnover for treating and predicting fracture risk risk of metabolic bone disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008979

Enrollment

400

Registered

2012-10-01

Start date

2010-06-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

given bisphosphonate in patient Given the 60 mg once daily Raloxifene in patients given the 0.5-1g once daily active type Vitamin D in patient receive 45 mg/day treatment of menatetrenone (MK-4)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: osteoporosis and metabolic bone disease

Exclusion criteria

Exclusion criteria: The patient who has been already treated with medicine for osteoporosis

Design outcomes

Primary

Measure	Time frame
new fracture	—

Secondary

Measure	Time frame
changes of biochemical markers of bone turnover and changes of the bone mineral density in lumbar and hip	—

Countries

Japan

Contacts

Public ContactHideki Masaki

Osaka City University Graduate School of Medicine Gerontology

h-masaki@med.osaka-cu.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026